glp 1 agonist benefits Frontiers Cardiovascular benefits of glucagon-like peptide-1

GLP-1 drugs are expensive, with list prices exceeding $1,000/month in many markets, and studies consistently show that people who stop taking semaglutide regain roughly two-thirds of the weight they lost, raising fundamental questions about whether these drugs represent treatment or lifelong pharmaceutical dependency

Semaglutide (Ozempic and Wegovy) resulted in a 14.9% reduction in body weight in clinical trials, while tirzepatide (Mounjaro and Zepbound) led to a 20.9% body weight reduction

Injection occurs once weekly on the same day

Brand-name pricing for tirzepatide and semaglutide will face downward pressure as more options reach market